List view / Grid view

Schizophrenia

Study shows contrasting cognitive effects of psychiatric drugs

5 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

A long-term study has found that low cumulative exposure to benzodiazepine does not affect cognition in schizophrenia...

news

Braeburn achieves endpoints in implant study to treat Schizophrenia

8 May 2017 | By Niamh Marriott, Junior Editor

Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia...

news

Alexza granted FDA approval of Adasuve sNDA to treat schizophrenia

11 October 2016 | By Niamh Louise Marriott, Digital Content Producer

Administration of Adasuve results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes...

news

EC approves Trevicta for the treatment of schizophrenia

1 June 2016 | By Victoria White, Digital Content Producer

The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...

news

CHMP adopts positive opinion of Trevicta for maintenance treatment of schizophrenia

5 April 2016 | By Victoria White

If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations...

news

Lundbeck starts Lu AF35700 Phase III programme in treatment-resistant schizophrenia

14 March 2016 | By Victoria White

The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...

news

Positive Phase 1b results for Heptares’ HTL9936

10 February 2016 | By Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...

news

FDA approves schizophrenia treatment Aristada

7 October 2015 | By Victoria White

Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...

news

New data released from QUALIFY study of aripiprazole once-monthly

24 June 2015 | By Victoria White

Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)...

news

Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia

9 June 2015 | By Victoria White

Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project - Open Translational Science in Schizophrenia...

news

Positive top-line results from Phase 3 trial of RBP-7000 in schizophrenia announced

6 May 2015 | By Victoria White

Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia...

news

Pierre Fabre Pharmaceuticals announce initiation of Phase IIa clinical trial program for F17464 in schizophrenia

3 February 2015 | By Pierre Fabre Pharmaceuticals

Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…

news

New real-world data highlight health and financial impact of caring for an adult with schizophrenia

11 November 2014 | By Janssen

Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation...

news

Lundbeck scientists part of group achieving breakthrough in understanding schizophrenia

23 December 2013 | By Lundbeck

New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...

news

Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia

21 September 2013 | By

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilised…

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Schizophrenia